355 related articles for article (PubMed ID: 25285810)
1. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema.
Al-Abdullah AA; Nowilaty SR; Asghar N; Al-Kharashi AS; Ghazi NG
Retina; 2015 Mar; 35(3):440-8. PubMed ID: 25285810
[TBL] [Abstract][Full Text] [Related]
2. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
[TBL] [Abstract][Full Text] [Related]
3. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant.
Lazic R; Lukic M; Boras I; Draca N; Vlasic M; Gabric N; Tomic Z
Retina; 2014 Apr; 34(4):719-24. PubMed ID: 23975006
[TBL] [Abstract][Full Text] [Related]
5. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
6. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment.
Bressler SB; Almukhtar T; Bhorade A; Bressler NM; Glassman AR; Huang SS; Jampol LM; Kim JE; Melia M;
JAMA Ophthalmol; 2015 May; 133(5):589-97. PubMed ID: 25719991
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
8. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS.
Pang CE; Mrejen S; Hoang QV; Sorenson JA; Freund KB
Retina; 2015 Jul; 35(7):1401-6. PubMed ID: 25650712
[TBL] [Abstract][Full Text] [Related]
9. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
Kiddee W; Montriwet M
PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
[TBL] [Abstract][Full Text] [Related]
10. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
[TBL] [Abstract][Full Text] [Related]
11. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
[TBL] [Abstract][Full Text] [Related]
12. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
[TBL] [Abstract][Full Text] [Related]
13. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
[TBL] [Abstract][Full Text] [Related]
14. The effect of intravitreal triamcinolone on intraocular pressure.
Kramar M; Vu L; Whitson JT; He YG
Curr Med Res Opin; 2007 Jun; 23(6):1253-8. PubMed ID: 17559723
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
16. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
17. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure.
Nariani A; Williams B; Hariprasad SM
Indian J Ophthalmol; 2016 Sep; 64(9):643-647. PubMed ID: 27853011
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
20. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
